



October 2009

## LAUNCHING OF OXYCODONE FLASHTAB<sup>®</sup> WITH MUNDI PHARMA

October 2009, Paris – France : Ethypharm announce the launch, by Mundipharma, in France and in Germany of an Orodispersible form of Oxycodone marketed under the name of OxynormOro<sup>®</sup> and Oxynorm Dispersa<sup>®</sup>. The product will then be marketed in other European countries in 2010.

This new orodispersible form has been developed on the basis of the Flashtab<sup>®</sup> technology. Mundipharma will launch it in extension of the Oxynorm capsule range.

Available in 3 dosage strengths (5, 10 & 20 mg), OxynormOro<sup>®</sup> and Dispersa<sup>®</sup> is indicated in the treatment of moderate to severe pain, notably of cancerous origin. The tablet disperses in less than 30 seconds on contact with the saliva and can be taken with or without water, thus facilitating administration and patient comfort.

Purdue/Napp/Mundipharma : a pioneer group and world reference in analgesics

Mundipharma is a private group of associated independent companies, i.e., Purdue / Napp / Mundipharma, specialized in pain relief and in the marketing of analgesic medicines by the oral route : MS Contin<sup>®</sup> and also OxyContin<sup>®</sup>, a modified release Oxycodone Tablet.

The Oxycodone market today represents an annual turnover of more than 200 million Euros, with an annual growth of 13%.

« We are very happy to announce this new launch with MundiPharma, who possess a large range of products in pain relief treatment. This successful partnership will enhance our leading position as a Partner in the development of pain relief products», said Bruno Delie, Ethypharm's Business and Marketing Director. "The Mundipharma expert marketing know-how in pain-relief medicines was a deciding element in the choice of this Partnership", he added.

About Ethypharm  
[www.ethypharm.com](http://www.ethypharm.com)

Ethypharm is a pharmaceutical laboratory specializing in controlled release systems of medicines for the oral route. Its principal therapeutic sectors concern pain relief, cardio-vascular and the central nervous system.

The Company has more than 50 products launched by marketing partners of high international repute in approximately 50 countries. Ethypharm develops and manufactures its products in conformity with the current world-wide pharmaceutical Norms. The Company has developed a large range of technological platforms for the administration of medicines by the oral route, including controlled release, orodispersible and taste-masked forms, and improved systems of solubility for active substances of low rate solubility.

Ethypharm is present on the principal world health markets with research and development centres and marketing productions in Europe, North America and Asia. The Laboratory employs 850 persons worldwide.